The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Evaluating nivolumab-based therapy to restore T-cell fitness in patients with R/R multiple myeloma
Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, describes a study which analyzed a subset of patients with multiple myeloma who relapsed post-CAR-T therapy, and subsequently received nivolumab. Whole-genome sequencing (WGS) and single-cell sequencing data were evaluated, and demonstrated that nivolumab may be used to restore T-cell fitness in some patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Massachusetts General Hospital: Current Employment; Two Seventy Bio: Research Funding; Research to Practice: Honoraria; Medscape: Honoraria; Amgen: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria; Celgene: Honoraria; Janssen: Consultancy, Honoraria.
